We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aurinia Pharmaceuticals (AUPH - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aurinia Pharmaceuticals is one of 947 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aurinia Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AUPH's full-year earnings has moved 20.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AUPH has returned about 72.9% since the start of the calendar year. In comparison, Medical companies have returned an average of 3.9%. This shows that Aurinia Pharmaceuticals is outperforming its peers so far this year.
Cardinal Health (CAH - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 67.4%.
In Cardinal Health's case, the consensus EPS estimate for the current year increased 4.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aurinia Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 146 individual stocks and currently sits at #84 in the Zacks Industry Rank. On average, stocks in this group have gained 5% this year, meaning that AUPH is performing better in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #99. The industry has moved +9.1% year to date.
Aurinia Pharmaceuticals and Cardinal Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aurinia Pharmaceuticals (AUPH - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Aurinia Pharmaceuticals is one of 947 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aurinia Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AUPH's full-year earnings has moved 20.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AUPH has returned about 72.9% since the start of the calendar year. In comparison, Medical companies have returned an average of 3.9%. This shows that Aurinia Pharmaceuticals is outperforming its peers so far this year.
Cardinal Health (CAH - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 67.4%.
In Cardinal Health's case, the consensus EPS estimate for the current year increased 4.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aurinia Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 146 individual stocks and currently sits at #84 in the Zacks Industry Rank. On average, stocks in this group have gained 5% this year, meaning that AUPH is performing better in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #99. The industry has moved +9.1% year to date.
Aurinia Pharmaceuticals and Cardinal Health could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.